



Top 21-25

09 June 2011 | News





Tel: +91-22-25848000 **Fax:** +91-22-25848475

Website: www.siroclinpharm.com

SIRO Clinpharm Private Limited (SIRO), clocked an estimated sales revenue of in202 ଫଟାର fort Fy type unknown 2010-11 when compared with in150 ଫଟାର in2009pe unknown

10. During early 2011, the CRO announced the launch of its operations in Malaysia and also announced strategic alliances with CROs in South Korea and Taiwan in 2010. The company is in the process of evaluating Philippines and Thailand amongst other Asian countries for expanding its clinical operations. SIRO has strategic alliances and partnerships with several firms such as Clingene, Pfizer and with Fisher Clinical services. SIRO is a member of Bundesverband Medizinischer Auftragsinstitute, the German Federal Association of Contract Research Organizations. SIRO's laurels include, conducting over 130 clinical trails, recruiting over 20,000 clincial trial subjects, passing over 240 audits by sponsor QA teams and working on USFDA, EMEA, UK MHRA, Korean FDA WHO Health Canada and DCGI submissions.

Image	e not found	or typ	Cadila Healthcare
			CEO Pankaj R Patel
			Business: Biologics and diagnostics

22

Start-up Year: 1995

Address: Cadila Healthcare Ltd., Zydus Tower, Satellite Cross Roads, Ahmedabad – 380015,Gujarat, INDIA

Tel: +91-79-26868100 Fax: +91-79-26862365

Website: www.zyduscadila.com

Revenue: In190:59 cfore*d or type unknown

Cadila Healthcare clocked biotech revenues worth image not found or type unknown 190.59 crore for FY 2010-11 as compared to the previous fiscal's revenue of 1947-48 crored or type unknown Presently, the firm has 15 biosimilars and two novel products in its pipeline. The company is also looking at biobetters for the future growth and has dedicated 120 scientists for this purpose. Zydus

looking at biobetters for the future growth and has dedicated 120 scientists for this purpose. Zydus Cadila acquired Italy-based, Etna Biotech, and the firm's Zydus Research Center (ZRC), has been working on strategic research collaboration with Prolong Pharmaceuticals, US, and Karo Bio, Sweden and Eli Lilly. Zydus Cadila has made swift progress on NME research and has 12 INDs in various stages of clinical trials and several more INDs in pre-clinical evaluation. The company also signed an agreement with Bayer HealthCare, in January 2011, to set up a joint venture company, Bayer Zydus Pharma, for the sales and marketing of pharmaceutical products in India.

Tulip Group

CEO
Dr Dilip Tripathi

Business: Manufacture and marketing of in vitro Diagnostic reagents and kits

Start-up Year: 1988

Address: Gitanjali, Tulip Block, Dr Antonio Do Rego Bagh, Alto Santacruz, Bambolim Complex Post Office, Goa - 403 202, INDIA

Tel: (0832) 2458546-51 Fax: (0832) 2458544

Website: www.tulipgroup.com

Tulip Group of companies clocked a total revenue of 1985.69 torrelier FY 2010 111 as against mage not found or type unknown 182.48 crore in FY 2009-10. Revenues from domestic sales for FY 2010-11 were 28:29t found or type unknown crore, while the firm reported exports worth mage not found or type unknown 57.40 crore. During the fiscal, the company made crore in R&D, 1020125 crore in infrastructure and 1 mage not found or type unknown 30.01 crore on manpower. The group has on its rolls a total staff of 1,033 people and consists of several individual companies such as Tulip Diagnostics, Microxpress, Orchid Biomedical Systems, Qualpro Diagnostics, Zephyr Biomedicals, Coral Clinical Systems, BioShields, Tulip Marketing, Crest Biosystems and Lilac Medicare. It also has marketing alliances with companies like Monobind, US; Orgentec, Germany and TOSOH, Japan. The company's products are distributed across 55 countries, it has a sales team of 325 personnel, has a customer base of over 15,000 and has 300 distributors.

CEO
Dr Hasit Joshipura

Business: Sales of vaccines and biologicals

GlaxoSmithKline (GSK) Pharmaceuticals, an affiliate of GlaxoSmithKline Biologicals, headquartered in Rixensart, Belgium, clocked an estimated sales of 17163 crotro in 2010419 lasknown compared to 1123:34torore in 2009-10:176day, GSK has a market share of 20 percent in the total Indian private vaccine segment. Vaccines contributed to nine to 10 percent of its total sales in the current year and in the coming years the company is looking at a growth of around 15 percent from its vaccines product portfolio. GSK India has 14 vaccines in its product basket. including Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed) and Cervarix, (human papillomavirus vaccine (types 16 and 18)) among others. The

Start-up Year:

2001

Address: Dr Annie Besant Road, Worli, Mumbai-40030

Tel: +91-22-24959205 Fax: +91-22-24914863

Website: www.gsk-india.com

Revenue: In163°crôré*und or type unknown

Revenue: In161ecroré ound or type unknown

Managing Director
Mr Amitabh Jaipuria

Business: Production and sale of herbicides, hybrid seeds and pesticides

Start-up Year: 1949

Address: Ahura Centre, 5th Floor, 96, Mahakali Caves Road, Andheri (East), Mumbai -400 093

Tel: +91-22-28246450 Fax: +91-22-26902121
Website: www.monsantoindia.com

Monsanto India clocked revenue sales of http:// not found or type unknown crore in FY 2010-11 as against http:// defore in or type unknown

2009-10. Monsanto has been selling Bt cotton hybrids in India for the last five years under Monsanto Holdings Private Limited (MHPL). MHPL is focused on marketing Paras cotton hybrid seeds with Bollgard and Bollgard Bt cotton technologies and Seminis vegetable hybrid seeds. It was estimated that the company sold about 18 lakh packets of Bollgard during the 2010 kharif season, which is an increase of two lakh as comapred to the same period in the last year. Monsanto has launched Project SHARE (Sustainable Harvest Agriculture, Resources, Environment), a sustainable yield initiative with an NGO called the Indian Society of Agribusiness Professionals (ISAP), to improve the socio-economic conditions of 10,000 small-marginal corn and cotton farmers in 1,100 villages in Andhra Pradesh, Maharashtra and Rajasthan within four years.